Gene mutation study results could lead to less expensive, more accessible breast and ovarian cancer screening

September 17, 2012
Gene mutation study results could lead to less expensive, more accessible breast and ovarian cancer screening

(Medical Xpress)—Researchers conducting a study of gene mutations that increase a woman's likelihood of breast and ovarian cancers have made a discovery that could open doors to less expensive and more accessible breast and ovarian cancer screening. Additionally, the surprising study results may also explain how human embryos with these breast cancer mutations survive.

The study, recently published by the prestigious online medical journal PLoS ONE, examined the of women who were known carriers of the mutated breast and ovarian gene BRCA1 and 2 (BRCA1/2). Women without BRCA1/2 mutations have a of 12% for breast and 1.4% for ovarian cancers. However, with a BRCA1/2 mutation, the risk for increases to 60% and for to 15-40%.

According to the results of the study, conducted by three teams of researchers from the Center for Human Reproduction (CHR) in New York, NY, USA; the Medical University Vienna in Vienna, Austria; and the Medical University Graz, in Graz, Austria; nearly all of the 99 subjects who were carriers of the BRCA1/2 mutations also had a very specific genotype known as "low" FMR1. In contrast, over 300 control subjects, who were not carriers of the mutated BRCA1/2 gene, showed normal distribution of the FMR1 genotypes with only about 25% of the subjects having the "low" FMR1. The authors concluded that because BRCA1/2 mutations are almost exclusively found in women with low FMR1, women without the low FMR1 genotype would not be at risk for BRCA1/2 mutations and, therefore, associated breast and ovarian cancer risks.

This link, according to researchers, suggests that less expensive FMR1 gene testing could be used in place of the current method of the costly BRCA1/2 screening for these cancer risks.

"We were very surprised by these results," said David H. Barad, MD, MS, Director of Clinical ART and Senior Scientist at CHR, a senior author of the study. "This observation, if confirmed, can greatly impact current cancer screening methods for BRCA1/2-associated cancers in women, and greatly reduce costs."

Currently, the only available genetic screening for breast and ovarian cancers is through the testing of the BRCA1/2 gene. However, due to the unusually high costs of the tests (about $3,000), testing is only recommended for women with a strong family history of these cancers. FMR1 testing, on the other hand, is available for as little as $400.

The authors note that the most likely explanation for why so many women with the BRCA1/2 mutation also have low FMR1 genotypes is that the BRCA1/2 mutation is lethal to ; only those embryos carrying a low FMR1 in addition to the BRC1/2 mutation survive, apparently rescued by the presence of a low FMR1 allele.

Further Study Implications: Solving the BRCA-paradox

The published report also notes that these findings may also help explain the mystery of the "BRCA-paradox," which has puzzled researchers for years. This paradox refers to the fact that BRCA1/2 mutation prevents cell growth and replication in embryonic tissue – making it lethal to a growing human embryo. However, in cancerous tissues, these mutations have exactly the opposite effect, allowing cancer cells to proliferate.

"Confirmed, these findings could mean that 'low' FMR1 alleles de-suppress the anti-proliferative activity of /2 in both tissues, in embryonic tissues allowing the embryo to survive, while in cancers having the negative effect of allowing cancer to proliferate," explains Norbert Gleicher, MD, Medical Director and Chief Scientist of CHR, and another senior author of the study. "This, of course, could open major therapeutic options for improving embryo growth and inhibiting cancer growth."

Explore further: Germ-line BRCA1/2 testing recommended in ovarian cancer

More information: Weghofer et al, BRCA1/2 mutations appear embryo-lethal unless rescued by low (CGG n<26) FMR1 sub-genotypes: Explanation for the "BRCA paradox"? PLoS ONE 2012; dx.plos.org/10.1371/journal.pone.0044753

"BRCA1 and BRCA2: Cancer Risk and Genetic Testing." National Cancer Institute at the National Institutes of Health. www.cancer.gov/cancertopics/factsheet/Risk/BRCA. 7 September 2012.

Related Stories

Germ-line BRCA1/2 testing recommended in ovarian cancer

June 19, 2012
(HealthDay) -- Due to the potential survival and treatment response implications of BRCA mutation status, it is recommended that germ-line BRCA1/2 testing be offered to all women diagnosed with nonmucinous ovarian carcinoma, ...

Gene inheritance patterns influence age of diagnosis in BRCA families

December 12, 2011
Women who inherit the cancer genes BRCA1 or BRCA2 from their paternal lineage may get a diagnosis a decade earlier than those women who carry the cancer genes from their mother and her ancestors, according to a new study ...

Recommended for you

Vitamin C may encourage blood cancer stem cells to die

August 17, 2017
Vitamin C may "tell" faulty stem cells in the bone marrow to mature and die normally, instead of multiplying to cause blood cancers. This is the finding of a study led by researchers from Perlmutter Cancer Center at NYU Langone ...

Scientists develop novel immunotherapy technology for prostate cancer

August 17, 2017
A study led by scientists at The Wistar Institute describes a novel immunotherapeutic strategy for the treatment of cancer based on the use of synthetic DNA to directly encode protective antibodies against a cancer specific ...

Outdoor light at night linked with increased breast cancer risk in women

August 17, 2017
Women who live in areas with higher levels of outdoor light at night may be at higher risk for breast cancer than those living in areas with lower levels, according to a large long-term study from Harvard T.H. Chan School ...

Toxic formaldehyde is produced inside our own cells, scientists discover

August 16, 2017
New research has revealed that some of the toxin formaldehyde in our bodies does not come from our environment - it is a by-product of an essential reaction inside our own cells. This could provide new targets for developing ...

Cell cycle-blocking drugs can shrink tumors by enlisting immune system in attack on cancer

August 16, 2017
In the brief time that drugs known as CDK4/6 inhibitors have been approved for the treatment of metastatic breast cancer, doctors have made a startling observation: in certain patients, the drugs—designed to halt cancer ...

Researchers find 'switch' that turns on immune cells' tumor-killing ability

August 16, 2017
Molecular biologists led by Leonid Pobezinsky and his wife and research collaborator Elena Pobezinskaya at the University of Massachusetts Amherst have published results that for the first time show how a microRNA molecule ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.